Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT03710681 Recruiting - Clinical trials for Moderate-to-severe Plaque Psoriasis

A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis

Start date: August 2, 2018
Phase: Phase 1
Study type: Interventional

This is a multiple dose escalating and open labeled clinical trial to evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple subcutaneous (s.c.) injections of SHR-1314 in adults with moderate-to-severe plaque psoriasis. The primary objective of this study is to investigate the safety and tolerability of multiple doses of subcutaneous SHR-1314 in subjects with moderate-to-severe plaque psoriasis. Secondary objectives are to determine the pharmacokinetics (PK) and immunogenicity profile of SHR-1314 in subjects with moderate-to-severe plaque psoriasis.

NCT ID: NCT03706209 Recruiting - Psoriasis Clinical Trials

Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis

Start date: February 27, 2018
Phase: Phase 2
Study type: Interventional

The primary objective of this trial is to evaluate the clinical efficacy and safety of two oral doses of MP1032 (150 mg bid and 300 mg bid) when taken for 12 weeks by patients with moderate-to-severe chronic plaque psoriasis.

NCT ID: NCT03701763 Not yet recruiting - Psoriasis Clinical Trials

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Start date: November 15, 2018
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis. At least 230 pediatric subjects (ages 6 through 17 years) will be randomized 2:1 to receive either apremilast or placebo for the first 16 weeks and then all subjects will receive apremilast during the 36 week Extension Phase for a total of 52 weeks. Randomization to apremilast arm or placebo arm will be stratified by age group (6 to 11 years or 12 to 17 years). Subjects will receive apremilast treatment of either 20 mg twice daily (BID) or 30 mg BID, depending on weight. This Phase 3 study is being conducted to evaluate the safety and efficacy of apremilast in the treatment of pediatric subjects.

NCT ID: NCT03675542 Not yet recruiting - Psoriasis Vulgaris Clinical Trials

The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis.

Start date: November 1, 2018
Phase: Phase 1
Study type: Interventional

This is a 12-week treatment, singlecenter, open-label, single-arm, dose-selection, proof of concept study to determine a dosage of HSP 90 inhibitor (CUDC-305) that is tolerable and demonstrates preliminary efficacy for use in future efficacy Phase 2 trials. Male or female subjects aged 18 years or older with moderate to severe plaque psoriasis will be included in this study. Objectives are to determine the efficacy, safety and tolerability of CUDC-305 in patients with moderate to severe psoriasis.

NCT ID: NCT03669757 Not yet recruiting - Psoriasis Vulgaris Clinical Trials

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis

Start date: September 2018
Phase: Phase 1
Study type: Interventional

To assess safety and tolerability after treatment with LEO 134310 cutaneous solution.

NCT ID: NCT03668613 Recruiting - Clinical trials for Moderate to Severe Chronic Plaque-type Psoriasis

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Start date: August 29, 2018
Phase: Phase 3
Study type: Interventional

This is an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis. Approximately 80 subjects (at least 60 subjects with moderate severity) will be enrolled. subjects will be stratified by weight. It is expected that subjects will be enrolled in about 40 centers worldwide.

NCT ID: NCT03662685 Recruiting - Psoriasis Clinical Trials

Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris

Start date: August 1, 2018
Phase: Phase 4
Study type: Interventional

This is a three-arm, open-label study, which will examine the effect of Goeckerman therapy (combination of phototherapy and topical crude coal tar), crude coal tar alone, and phototherapy alone on the immunologic and genetic environment within psoriatic lesions.

NCT ID: NCT03661866 Not yet recruiting - Psoriasis Clinical Trials

A 5-year Study of Patients Treated for Atopic Dermatitis and Other IMISC

TARGET-DERM
Start date: October 1, 2018
Phase:
Study type: Observational [Patient Registry]

TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

NCT ID: NCT03656627 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Phase 1B Study of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

Start date: October 31, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to explore the safety, tolerability and activity of Nivolumab, a PD-1 inhibitor, in cohorts of patients with autoimmune disease. Two cohorts of patients will be enrolled, based on autoimmune disease type. Patients will be screened within 28 days prior to the start of dosing. Eligible patients will be enrolled in either of the two cohorts. Patients will receive treatment every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle. Subjects will be permitted to continue treatment beyond initial RECIST 1.1.

NCT ID: NCT03645499 Recruiting - Plaque Psoriasis Clinical Trials

An Open-Label Study to Assess Safety

Start date: April 4, 2018
Phase: Phase 2
Study type: Interventional

An Open-Label study to assess safety